ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ASTH vs PG // GROSS PROFIT MARGIN

Astrana Health Inc. (NASDAQ) VS. Procter & Gamble Company (NYSE) • 15-METRIC TALLY: ASTH 2 — PG 10
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASTH VS. PG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ASTH PG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — 51.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 4.60% 25.40% -20.80 PG /roic <GO>
EV/EBITDA & P/E Valuation 27.3x 16.2x +11.10 PG /valuation <GO>
Free Cash Flow Yield 5.75% 3.77% +1.98 ASTH /fcf-yield <GO>
Operating Margin 2.50% 24.30% -21.80 PG /operating-margins <GO>
Net Profit Margin 0.80% 19.00% -18.20 PG /net-margins <GO>
Revenue Growth (YoY) 56.40% 0.30% +56.10 ASTH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.43% 2.65% -2.22 PG /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.54 5.59 -3.05 PG /balance-sheet <GO>
Piotroski F-Score Quality 6/9 7/9 -1.00 PG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.3 60.3 -13.00 PG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.87 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 63.6x 21.7x +41.90 PG /forward-pe <GO>
Enterprise Scale & Market Cap $1.82B $372.21B -$370.40B PG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ASTH REV PG REV ASTH GROSS % PG GROSS % ASTH FCF PG FCF
FY 2025 $3.18B $84.28B — 51.2% $104.5M $14.04B
FY 2024 $2.03B $84.04B — 51.4% $44.2M $16.52B
FY 2023 $1.39B $82.01B — — $68.2M $13.16B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASTH // BETA —
PG // BETA 0.87